Quent Capital, LLC Biomarin Pharmaceutical Inc Call Options Transaction History
Quent Capital, LLC
- $882 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BMRN
# of Institutions
618Shares Held
181MCall Options Held
1.73MPut Options Held
1.73M-
Primecap Management CO Pasadena, CA18.7MShares$1.59 Billion1.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$1.54 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.23 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA14MShares$1.19 Billion0.75% of portfolio
-
State Street Corp Boston, MA6.9MShares$586 Million0.03% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $15.8B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...